Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Authors
Keywords
-
Journal
JOURNAL OF NEUROENDOCRINOLOGY
Volume -, Issue -, Pages e12664
Publisher
Wiley
Online
2018-11-23
DOI
10.1111/jne.12664
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
- (2018) IN YOUNG CHOI et al. DIABETES
- MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus
- (2018) MEENA JAIN et al. DIABETES
- EJE PRIZE 2018: A gut feeling about glucagon
- (2018) Filip K Knop EUROPEAN JOURNAL OF ENDOCRINOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
- (2018) Lærke Smidt Gasbjerg et al. PEPTIDES
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
- (2017) Tricia Tan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight
- (2017) L López-Ferreras et al. MOLECULAR PSYCHIATRY
- Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus
- (2017) Ji Liu et al. NEURON
- Weight and Metabolic Outcomes 12 Years after Gastric Bypass
- (2017) Ted D. Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health Effects of Overweight and Obesity in 195 Countries over 25 Years
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
- (2017) Laurie L. Baggio et al. Molecular Metabolism
- Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
- (2017) Sigrid Jall et al. Molecular Metabolism
- Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
- (2016) Tianru Jin et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
- (2016) Lydia Lynch et al. Cell Metabolism
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- Evolving Concepts and Translational Relevance of Enteroendocrine Cell Biology
- (2016) Daniel J. Drucker JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men
- (2014) Julie Berg Schmidt et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
- (2014) Jaimini Cegla et al. DIABETES
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications
- (2013) Louise Albertsen et al. ACS Medicinal Chemistry Letters
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
- (2012) T. M. Tan et al. DIABETES
- Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
- (2012) Michael Horowitz et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
- (2012) Jennifer R. Kosinski et al. Obesity
- The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans
- (2011) Akila De Silva et al. Cell Metabolism
- Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
- (2011) Victor A. Gault et al. CLINICAL SCIENCE
- PYY3-36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
- (2010) B. C. T. Field et al. DIABETES
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Effects of central administration of glucagon on feed intake and endocrine responses in sheep
- (2009) Yohei KUROSE et al. ANIMAL SCIENCE JOURNAL
- Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- (2009) C. Daousi et al. CLINICAL ENDOCRINOLOGY
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice
- (2008) Nigel Irwin et al. REGULATORY PEPTIDES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now